Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest update is out from Amur Minerals ( (GB:CRTX) ).
CRISM Therapeutics Corporation has been granted a European patent for its lead product, ChemoSeed, which focuses on the localized delivery of chemotherapeutic drugs, specifically irinotecan, to treat brain tumors such as high-grade glioma. This patent marks a significant milestone for the company, providing intellectual property protection in a key market and enhancing the product’s appeal to potential commercial partners. The company plans to advance towards clinical trials in 2025, with hopes of improving therapeutic outcomes for brain tumor patients.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based company that specializes in innovative drug delivery technologies aimed at improving the clinical performance of cancer treatments for solid tumors. Their primary product, ChemoSeed, is designed for localized delivery of chemotherapy drugs, particularly for treating high-grade glioma by implanting therapeutic agents directly into tumor sites.
YTD Price Performance: -18.40%
Average Trading Volume: 24,111
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £1.02M
For detailed information about CRTX stock, go to TipRanks’ Stock Analysis page.
